Arena Pharmaceuticals (ARNA) Trades Down Following Stock Offering
Tweet
Share
E-mail
Get Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) is initially trading down 3 percent following the announcement of a stock offering after the close Tuesday.
The company didn't provide an amount but said the offering will be made through Jefferies & Company, Inc. and Piper Jaffray & Co.
Arena surged recently following FDA panel backing of its obesity drug Lorcaserin.
The company didn't provide an amount but said the offering will be made through Jefferies & Company, Inc. and Piper Jaffray & Co.
Arena surged recently following FDA panel backing of its obesity drug Lorcaserin.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
- Phillips 66, Marathon Merger Talks Collapsed - Semafor
- Coherent earnings preview: Analysts say this is the key unlock to outperformance
Create E-mail Alert Related Categories
Equity Offerings, Momentum Movers, Trader TalkRelated Entities
Piper Jaffray, Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
